Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry Eye

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-09

Study Completion Date

2019-12-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore the efficacy and safety of CsA ophthalmic gel in the treatment of moderate to severe tear deficiency dry eye with different dosage, frequency and concentration, and to preliminarily determine the optimal dosage, frequency and concentration, so as to provide a theoretical basis for the design of follow-up clinical studies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease

NCT04541888

Dry Eye

COMPLETED PHASE3

A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients

NCT06942793

Dry Eye Disease

NOT_YET_RECRUITING PHASE3

A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease

NCT06766357

Moderate to Severe Dry Eye

RECRUITING PHASE3

The Effect of 0.05% CsA Eye Drops on Diabetic Patients with Dry Eye Disease

NCT06824844

Dry Eye

COMPLETED PHASE4

Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

NCT03287635

Dry Eye Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A multicenter, randomized, single-blind, positive controlled exploratory study will be conducted with cyclosporine A ophthalmic emulsion as the control drug.

The experimental drugs were divided into three groups:

Treatment group A: CsA eye gel: 0.3 g: 0.15 mg, once daily； Treatment group B: CsA eye gel: 0.3 g: 0.15 mg, twice daily, interval of about 12 hours； Treatment group C: CsA eye gel: 0.3 g: 0.3 mg, once daily. One drop into each eye when you use it.

Control group: CsA emulsion: 0.4 ml: 0.2 mg. One drop into the eye, 2 times daily with an interval for 12 hours.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.3 g: 0.15 mg（1)&Hypromellose Eye Drops

Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.

Group Type EXPERIMENTAL

CsA eye gel

Intervention Type DRUG

The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg

Hypromellose Eye Drops

Intervention Type DRUG

Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop

0.3 g: 0.15mg（2)&Hypromellose Eye Drops

Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.

Group Type EXPERIMENTAL

CsA eye gel

Intervention Type DRUG

The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg

Hypromellose Eye Drops

Intervention Type DRUG

Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop

0.3 g: 0.3 mg &Hypromellose Eye Drops

Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.3 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.

Group Type EXPERIMENTAL

CsA eye gel

Intervention Type DRUG

The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg

Hypromellose Eye Drops

Intervention Type DRUG

Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop

0.4 ml: 0.2 mg &Hypromellose Eye Drops

Sixty subjects will be treated with CsA for eye emulsion: 0.4 ml: 0.2 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.

Group Type ACTIVE_COMPARATOR

CsA for eye emulsion

Intervention Type DRUG

The CsA for eye emulsion of 0.4 ml: 0.2 mg

Hypromellose Eye Drops

Intervention Type DRUG

Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CsA eye gel

The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg

Intervention Type DRUG

CsA for eye emulsion

The CsA for eye emulsion of 0.4 ml: 0.2 mg

Intervention Type DRUG

Hypromellose Eye Drops

Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CsA gel CsA emulsion zhenshishuang

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥18, both male and female;
2. Pregnancy tests were negative for women of childbearing age and contraceptive measures (including abstinence, intrauterine devices, diaphragms and spermicides) were taken during the trial. Men are willing to use approved contraceptive methods (possibly using condoms and spermicides or oral contraceptives, implants or injections of contraceptives, intrauterine devices, diaphragms and spermicides) or sexual partner infertility;
3. According to the symptoms and signs and ophthalmologic examinations, the patients were diagnosed as moderate to severe dry eye;

1. EDS score is more than 40 points;
2. BUT is less than 10 s;
3. Schirmer test result is less than 10mm/5 min;
4. In any area, corneal fluorescein staining was more than 2 points.
4. The anatomy of the eyelids is normal and has normal blinking function;
5. Patients with newly diagnosed dry eye disease, or who are undergoing dry eye treatment, voluntarily discontinue treatment within 72 hours of entering the screening period;
6. Ability and willingness to participate in all research assessments and all planned visits during the pilot period in accordance with the programme requirements;
7. Agree to participate in the study and voluntarily sign informed consent.

Exclusion Criteria

1. Allergy to CsA, fluorescein or any component of the drug is known;
2. Severe dry eye patients requiring surgical treatment;
3. Glaucoma patients;
4. Unwilling to avoid wearing contact lenses;
5. Within 12 months prior to the start of the study, intraocular surgery or internal surgery was necessary;
6. Eyelid surgery was performed within 6 months prior to the start of the study, or dry eye secondary to surgery;
7. Those who had undergone corneal refractive surgery or keratoplasty;
8. Congenital lacrimal gland or meibomian gland deficiency or lacrimal gland obstructive diseases;
9. Systemic inflammation or active eye infection and blepharitis;
10. Patients with ocular cicatricial pemphigoid, obvious conjunctival scar, ocular chemical burn and neurotrophic keratoconjunctivitis;
11. Who suffered from ocular malignancies;
12. No other eye drops could be stopped during the study period;
13. Systemic or uncontrollable disorders that affect the collection of research parameters or patient compliance, such as severe cardiopulmonary disease, uncontrollable hypertension and diabetes;
14. With history of central nervous system disease or epilepsy, and / or mental disorder;
15. Pregnant women and lactating women, or women of childbearing age, do not adopt effective contraceptive measures;
16. Participated in other clinical trials or participated in other clinical trials within 1 months before the election;
17. Systemic or topical cyclosporine drugs within 3 months;
18. Patients who were not considered suitable for the study, including those who were unable or unwilling to comply with the protocol requirements.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No